Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to discuss the use of medication to treat mental health and the ...

Also Read: Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know. Results showed VK0214 to be safe and well-tolerated following ...

Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and efficacy of the oral version of its investigational obesity drug VK2735.

Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing it closer to joining the highly competitive GLP-1 drug market, STAT tells us.

Viking previously reported positive results from ... Semaglutide is a GLP-1 receptor agonist that has been approved by the U.S. Food and Drug Administration and is currently marketed in various ...

Hsieh also said Viking's pill showed a "highly benign tolerability profile," referring to how well patients tolerated the drug. Six of nine ... protect the patient's health. Abortions are ...

Health care companies fell as traders fled risky niches of the sector. Shares of Viking Therapeutics slid ... called "rapid" enrollment for the drug developer's widely anticipated obesity drug ...

Maggie O’Neill is a health writer and ... would work similarly to other medications in this category, such as Zepbound and Mounjaro. Some companies, including Viking Therapeutics and AstraZeneca ...

Besides, Viking Therapeutics already has an oral GLP-1 more advanced and a Chinese drug candidate doesn't exactly seem ideal in the current state of global affairs. The small biotech released data ...

Health care companies fell as traders fled risky niches of the sector. Shares of Viking Therapeutics slid ... called "rapid" enrollment for the drug developer's widely anticipated obesity drug ...